Baird served as co-manager on this offering
AboutMarinus Pharmaceuticals, Inc. (“Marinus” or the “Company”) (NASDAQ:MRNS) recently completed a follow-on offering of 12,000,000 shares of common stock at a price to the public of $3.75 per share for total gross proceeds of $45 million. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,800,000 shares of common stock. Marinus intends to use the net proceeds received from the sale of its common stock to advance the preclinical and clinical development of ganaxolone, including clinical trial expenses, including trials for postpartum depression and its rare pediatric refractory epilepsy program, and regulatory, research and development, pre-commercial, general and administrative and manufacturing expenses and for working capital and general corporate purposes.
Marinus is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders. Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in three different dose forms (IV, capsule and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus has initiated the first ever pivotal study in children with CDKL5 deficiency disorder, a rare form of epilepsy, and is currently conducting studies in patients with postpartum depression and refractory status epilepticus. Marinus is headquartered in Radnor, Pennsylvania.
CONTACT US TO LEARN MORE
- December 2018
- Marinus Pharmaceuticals, Inc.
- Target Location
- North America